Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva

Study ID
GOG-0279

Cancer Related
Yes

Healthy Volunteers
No

Study Sites

  • Clements University Hospital
  • UT Southwestern Ambulatory Services
  • Zale Lipshy University Hospital
  • Parkland Health & Hospital System

Contact
Annette Paulsen
214/648-2290
annette.paulsen@utsouthwestern.edu

Principal Investigator
David Miller

Official Title

A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva

Brief Overview


This phase II trial studies how well giving radiation therapy together with gemcitabine
hydrochloride and cisplatin work in treating patients with locally advanced squamous cell
carcinoma of the vulva. Specialized radiation therapy that delivers a high dose of radiation
directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Giving radiation therapy together with gemcitabine hydrochloride and
cisplatin may kill more tumor cells.

Summary


PRIMARY OBJECTIVES:

I. To determine the efficacy of cisplatin, gemcitabine (gemcitabine hydrochloride), and
Intensity-Modulated Radiation Therapy (IMRT) in achieving a complete pathologic response
when used for the primary treatment of locally-advanced squamous cell carcinoma of the
vulva.

SECONDARY OBJECTIVES:

I. To determine the efficacy of cisplatin, gemcitabine, and IMRT in achieving a complete
clinical response when used for the primary treatment of locally-advanced squamous cell
carcinoma of the vulva.

II. To determine the vulvar progression-free survival and groin progression-free survival in
women treated with cisplatin, gemcitabine and IMRT for locally advanced vulvar carcinoma.

III. To determine the toxicity and surgical morbidity of the combined modality approach of
cisplatin, gemcitabine and IMRT followed by reduced-scope surgery for the treatment of
locally-advanced vulvar carcinoma.

OUTLINE:

Patients undergo IMRT 5 days a week for 6 weeks. Patients also receive gemcitabine
hydrochloride intravenously (IV) over 30 minutes and cisplatin IV over 60 minutes weekly for
6 weeks in the absence of disease progression or unacceptable toxicity. Within 6-8 weeks
after completion of chemoradiation patients undergo local core biopsy to confirm response or
surgical excision of gross residual disease in the vulva and/or inguinal-femoral lymph
nodes.

After completion of study treatment, patients are followed up every 3 months for 2 years and
then every 6 months for 3 years.

Participant Eligibility


Inclusion Criteria:

- Patients with locally advanced, previously untreated squamous cell carcinoma of the
vulva

- Patients with T2 or T3 primary tumors (N0-3, M0) not amenable to surgical resection
by standard radical vulvectomy

- Absolute neutrophil count (ANC) >= 1,500/mcl

- Platelets >= 100,000/mcl

- Creatinine =< 1.5 times institutional upper limit of normal (ULN) OR calculated
creatinine clearance >= 60 mL/min

- Bilirubin =< 1.5 x ULN

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN

- Alkaline phosphatase =< 3 x ULN

- Patients judged capable of tolerating a radical course of chemoradiation therapy

- Patients must not be eligible for a higher priority Gynecologic Oncology Group (GOG)
protocol, if one exists; in general, this would refer to any active GOG Phase III
protocol or Rare Tumor protocol for the same patient population

- Patients must have signed an approved informed consent and authorization permitting
release of personal health information

- Patients with a GOG performance status of 0, 1, or 2

Exclusion Criteria:

- Patients with recurrent carcinoma of the vulva regardless of previous treatment

- Patients who have received prior pelvic radiation or cytotoxic chemotherapy

- Patients with vulvar melanomas or sarcomas

- Patients with circumstances that will not permit completion of the study or the
required follow-up

- Patients with evidence of active septicemia, severe infection, gastrointestinal
bleeding or severe gastrointestinal symptoms requiring medical or surgical therapy

- Patients with a history of other invasive malignancies, with the exception of
non-melanoma skin cancer, are excluded if there is any evidence of other malignancy
being present within the last five years; patients are also excluded if their
previous cancer treatment contraindicates this protocol therapy